Payment overview · 2025
General Payments
$5,810.22
205 reported records · 38 companies
Healthcare provider profile · identity verified
Daniel H Donovan, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · COOKEVILLE, TN · NPI 1629068994
Verified facts
What the public records show
CMS Open Payments records show Daniel H Donovan, MD received $5,810.22 in general payments during 2025 across 205 reported records.
HEARTFLOW, INC. accounted for 26.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Briviact, Evrysdi, Nuplazid, Nurtec Odt, Qulipta, Vraylar, Vumerity.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Vraylar by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rytary by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Vumerity by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Fycompa by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Evrysdi as an associated drug or biological on 569 records involving 252 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Evrysdi by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nurtec Odt by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Austedo by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $1,526.01 | 26.3% | 6 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $555.46 | 9.6% | 22 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $436.89 | 7.5% | 14 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $323.67 | 5.6% | 27 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $273.76 | 4.7% | 12 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $252.55 | 4.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $237.15 | 4.1% | 14 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $230.08 | 4.0% | 10 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $182.36 | 3.1% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $170.13 | 2.9% | 14 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $169.70 | 2.9% | 6 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $154.19 | 2.6% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $117.26 | 2.0% | 6 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $108.68 | 1.9% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$93.47 | 1.6% | 5 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $92.96 | 1.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $92.93 | 1.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.60 | 1.3% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $72.29 | 1.2% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $68.72 | 1.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $54.47 | 0.9% | 3 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $49.02 | 0.8% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $48.97 | 0.8% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.80 | 0.8% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $41.24 | 0.7% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $39.68 | 0.7% | 2 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $38.90 | 0.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $35.81 | 0.6% | 2 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $33.01 | 0.6% | 2 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $24.96 | 0.4% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $24.93 | 0.4% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $24.50 | 0.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.00 | 0.4% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $21.85 | 0.4% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.29 | 0.3% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $19.39 | 0.3% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$17.58 | 0.3% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $13.96 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,204.99 | 197 |
| Travel and Lodging | $1,296.76 | 4 |
| Education | $308.47 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $1,526.01 | 6 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $387.80 | 11 | 2025 |
Source payment records
|
|||||
| VNS Therapy Normalized: vns therapy |
Device | LivaNova USA, Inc. | $252.55 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $230.08 | 10 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $220.71 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $196.97 | 11 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $193.11 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $188.03 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $170.13 | 14 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $170.13 | 14 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $169.70 | 6 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $156.69 | 25 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $154.46 | 7 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $148.76 | 7 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $120.49 | 4 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $117.26 | 6 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $108.68 | 4 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $92.96 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $92.93 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $72.29 | 3 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $68.72 | 3 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $65.50 | 3 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $54.47 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $49.02 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $48.97 | 3 | 2025 |
Source payment records
|
|||||
| Evrysdi Normalized: evrysdi |
Drug | Genentech USA, Inc. | $48.86 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $45.80 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $41.24 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $39.68 | 2 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $38.90 | 2 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $38.49 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $38.49 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.11 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $35.81 | 2 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $33.01 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $31.79 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $27.90 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $25.50 | 2 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $7.59 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Evrysdi evrysdi |
2025 | Evrysdi | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Evrysdi open payments reported associated product |
CMS Open Payments — General Payments 569 supporting records · 252 recipient NPIs · example record 1211488410 |
Evrysdi · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 350 | 62 |
| Memantine Hcl | Memantine Hcl | 322 | 87 |
| Lamotrigine | Lamotrigine | 316 | 70 |
| Clonidine Hcl | Clonidine Hcl | 226 | 49 |
| Trazodone Hcl | Trazodone Hcl | 203 | 49 |
| Levetiracetam | Levetiracetam | 184 | 41 |
| Bupropion Xl | Bupropion Hcl | 168 | 38 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 163 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 162 | 36 |
| Sertraline Hcl | Sertraline Hcl | 145 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 123 | 29 |
| Donepezil Hcl | Donepezil Hcl | 110 | 40 |
| Pregabalin | Pregabalin | 101 | 15 |
| Primidone | Primidone | 98 | 26 |
| Clonidine | Clonidine | 92 | 20 |
| Olanzapine | Olanzapine | 85 | 16 |
| Clonazepam | Clonazepam | 75 | 15 |
| Dalfampridine Er | Dalfampridine | 73 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 72 | 18 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 69 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 68 | 11 |
| Temazepam | Temazepam | 66 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 65 | 22 |
| Prednisone | Prednisone | 64 | 12 |
| Mirtazapine | Mirtazapine | 62 | 18 |
| Topiramate | Topiramate | 62 | 13 |
| Baclofen | Baclofen | 61 | 13 |
| Oxcarbazepine | Oxcarbazepine | 58 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 53 | suppressed |
| Entacapone | Entacapone | 51 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 50 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 48 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 45 | 13 |
| Alprazolam | Alprazolam | 44 | 12 |
| Atomoxetine Hcl | Atomoxetine Hcl | 44 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 44 | 13 |
| Vraylar | Cariprazine Hcl | 43 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 42 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 41 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 41 | suppressed |
| Zonisamide | Zonisamide | 41 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 40 | suppressed |
| Diazepam | Diazepam | 40 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 39 | suppressed |
| Amantadine | Amantadine Hcl | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Aripiprazole | Aripiprazole | 36 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Vumerity | Diroximel Fumarate | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Modafinil | Modafinil | 31 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 31 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 30 | suppressed |
| Perphenazine | Perphenazine | 30 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 28 | suppressed |
| Briviact | Brivaracetam | 26 | suppressed |
| Lamictal | Lamotrigine | 25 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 22 | suppressed |
| Armodafinil | Armodafinil | 21 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 20 | suppressed |
| Sodium Oxybate | Sodium Oxybate | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 19 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 19 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Clozapine | Clozapine | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Evrysdi | Risdiplam | 15 | suppressed |
| Fycompa | Perampanel | 15 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 15 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 15 | suppressed |
| Rytary | Carbidopa/Levodopa | 15 | suppressed |
| Botox | Onabotulinumtoxina | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Copaxone | Glatiramer Acetate | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Kesimpta Pen | Ofatumumab | 14 | suppressed |
| Austedo | Deutetrabenazine | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 13 | suppressed |
| Teriflunomide | Teriflunomide | 13 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Aubagio | Teriflunomide | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Levocarnitine | Levocarnitine | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 11 | suppressed |
| Levetiracetam Er | Levetiracetam | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,810.22 · 205 records | HEARTFLOW, INC. | AMPYRA, AMYVID, AUSTEDO XR, Azstarys, BOTOX, Bafiertam, Briviact, CAPLYTA, CREXONT, Dyanavel XR, EPIDIOLEX, Evrysdi, FANAPT, FFRct, FIRDAPSE, Fintepla, Gamunex-C, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, LUMRYZ, Leqembi, MOUNJARO, NUPLAZID, NURTEC ODT, Nayzilam, Ocrevus, Ocrevus Zunovo, QULIPTA, QUTENZA, REXULTI, Rystiggo, SKYCLARYS, Symbravo, TRUDHESA, UBRELVY, ULTOMIRIS, VALTOCO, VNS Therapy, VRAYLAR, VUMERITY, VYEPTI, VYVGART HYTRULO, WAINUA, XYWAV, Xeomin, ZAVZPRET, ZEPBOUND, ZEPOSIA | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error